← All trials
NCT05171855
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Dec 29, 2021
- Last posted
- Sep 2, 2022
- Enrollment
- 240
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascendis Pharma, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.